Apogee Therapeutics Inc
Research Apogee Therapeutics Inc (APGE) on Bullrun: market cap USD 10.00B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAPGE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.00B
- Financial periodFY2025
- Net income-USD 255.84M
- Free cash flow-USD 232.60M
Valuation Snapshot
latest market cap is USD 10.00B.
About Apogee Therapeutics Inc
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials;
Frequently asked questions
What is Apogee Therapeutics Inc's market cap?
Apogee Therapeutics Inc's market capitalization is USD 10.00B.
What does Apogee Therapeutics Inc do?
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.